|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Dr. Sean Emerson George||Co-Founder, Pres, CEO & Chairman||666,79k||N/A||1974|
|Ms. Shelly D. Guyer||Chief Financial Officer||566,77k||N/A||1960|
|Dr. Robert L. Nussbaum||Chief Medical Officer||500,09k||109,4k||1950|
|Mr. Lee Bendekgey||Chief Policy Officer||566,77k||N/A||1958|
|Ms. Katherine A. Stueland||Chief Commercial Officer||545,13k||N/A||1976|
|Mr. Alex Furman||Co-Founder, Culture Tsar & Head of People Analytics||N/A||N/A||N/A|
|Ms. Michele Cargill Ph.D.||Co-Founder, Key Projects & Advisor to the CEO||N/A||N/A||N/A|
|Mr. Kenneth D. Knight||Chief Operating Officer||N/A||N/A||1960|
|Mr. Robert F. Werner||Chief Accounting Officer||N/A||N/A||1973|
|Mr. Layton Wedgeworth||Chief Technology Officer||N/A||N/A||N/A|
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy; and a project with Bristol Myers Squibb, Janssen Research & Development, LLC, Novartis, and Genentech to develop a panel for molecular residual disease detection in patients with acute myeloid leukemia to support clinical trial testing across various drug development programs. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
El ISS Governance QualityScore de Invitae Corporation, a día 2 de diciembre de 2020, es 6. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 8; Compensación: 7.